|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunosuppressant
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L04AA23
|
|
gptkbp:brand
|
gptkb:Tysabri
|
|
gptkbp:CASNumber
|
189261-10-7
|
|
gptkbp:contraindication
|
active infection
history of PML
|
|
gptkbp:developer
|
gptkb:Biogen
gptkb:Elan
|
|
gptkbp:drugClass
|
immunotherapy
humanized monoclonal antibody
|
|
gptkbp:eliminationHalfLife
|
11 days
|
|
gptkbp:firstApprovedCountry
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:hasMolecularFormula
|
C6470H9956N1732O2012S42
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Natalizumab
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits alpha-4 integrin
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
hypersensitivity reactions
liver injury
increased risk of infections
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:progressive_multifocal_leukoencephalopathy
fatigue
headache
allergic reaction
|
|
gptkbp:target
|
gptkb:alpha-4_beta-1_integrin
gptkb:alpha-4_beta-7_integrin
|
|
gptkbp:UNII
|
4Z2C2DVIKC
|
|
gptkbp:usedFor
|
gptkb:Crohn's_disease
multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Biogen_Inc.
|
|
gptkbp:bfsLayer
|
7
|